Certican (Everolimus) Against Cytomegalovirus Disease in Renal Transplant Patients.

Trial Profile

Certican (Everolimus) Against Cytomegalovirus Disease in Renal Transplant Patients.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Everolimus (Primary) ; Ganciclovir; Valganciclovir
  • Indications Cytomegalic inclusion disorders
  • Focus Therapeutic Use
  • Acronyms Certi-CMV
  • Most Recent Events

    • 20 Jan 2017 This trial was completed in Austria (end date: 2016-08-29), according to European Clinical Trials Database.
    • 31 Aug 2012 Planned End Date changed from 1 Jun 2012 to 1 Jun 2014 as reported by ClinicalTrials.gov
    • 06 Sep 2011 Additional lead investigator identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top